胃不全麻痺治療の世界市場

胃不全麻痺治療の世界市場は2030年までに77億米ドルに到達

2024年に64億米ドルと推定される胃不全麻痺治療の世界市場は、分析期間2024-2030年にCAGR 3.2%で成長し、2030年には77億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである催吐薬は、CAGR 4.5%を記録し、分析期間終了時には30億米ドルに達すると予想されます。制吐剤セグメントの成長率は、分析期間中CAGR 2.3％と推定されます。

米国市場は17億米ドルと推定、中国はCAGR6.3％で成長予測

米国の胃不全麻痺治療市場は2024年に17億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに15億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.2%と2.6%と予測されています。欧州では、ドイツがCAGR 1.8%で成長すると予測されています。

世界の胃不全麻痺治療市場- 主要動向と促進要因のまとめ

胃不全麻痺治療が消化器領域で注目される理由とは？

胃の筋肉が食物を消化管を通して適切に移動させることができない状態である胃不全麻痺は、その有病率の増加や患者のQOLに大きな影響を与えることから、消化器内科領域でますます重要な焦点となりつつあります。この疾患は、糖尿病などの基礎疾患に起因することが多く、吐き気、嘔吐、腹部膨満感、早期満腹感、激しい腹部不快感などの症状を引き起こします。糖尿病の罹患率が世界的に上昇するにつれて、糖尿病性神経障害に関連した胃不全麻痺の症例数も増加しており、慢性疾患の管理における大きな懸念となっています。胃不全麻痺は原因が多面的であり、症状も多様であるため、治療が大きな課題となっています。患者はしばしば長期的な管理戦略に苦慮し、高レベルのフラストレーション、生産性の低下、全体的なQOLの低下につながります。さらに、胃不全麻痺は栄養不足と体重減少を引き起こすことが多く、胃腸の問題だけでなく、代謝の問題としても重要です。その結果、この状態をよりよく管理するために、薬物療法、食生活の改善、技術的介入など、より効果的な治療に対する需要が高まっています。胃不全麻痺と他の慢性疾患との関連に対する認識の高まりは、症状コントロールと患者の転帰を改善することを目的とした、解決策を見出すためのより大きな研究努力と投資につながっています。

胃不全麻痺治療の進歩はどのように患者ケアを改善しているのか？

胃不全麻痺の治療における進歩は、この課題である胃不全麻痺を管理する能力を大きく向上させ、患者ケアを向上させました。従来、胃不全麻痺の治療には、食事療法、運動促進薬、吐き気や嘔吐の緩和を目的とした対症療法が併用されてきました。しかし、最近の開発動向は治療選択肢を広げ、対症療法の有効性を向上させています。重要な進歩のひとつは、胃の運動を刺激する新しい運動促進薬の導入です。歴史的に治療の中心であったメトクロプラミドのような治療薬は、現在では、副作用が少なく、患者の忍容性がより高い、ドーパミン拮抗薬や5-HT4作動薬のような新しい選択肢によって補完されつつあります。さらに、胃電気刺激（GES）は、従来の治療に反応しない難治性胃不全麻痺患者に対する有望な治療法として登場してきました。この方法は、胃の筋肉に電気パルスを送る装置を埋め込むもので、運動性を改善し、吐き気や嘔吐などの症状を緩和します。治療におけるもう一つの画期的な進歩は、制吐剤や輸液などの点滴療法を用いて、重度の胃不全麻痺患者によくみられる脱水や栄養不足を管理することです。さらに、食事管理も専門的な栄養介入によって進歩しており、必要な場合には流動食や経腸栄養を使用することで、患者が状態を管理しながら十分な栄養を維持できるようになっています。これらの治療法の進歩は、胃排出シンチグラフィーのような診断技術の向上と相まって、胃不全麻痺の重症度を評価するのに役立ち、胃不全麻痺を患っている患者に対して、より個別化された効果的な治療計画を可能にしています。

胃不全麻痺治療市場の成長を促進する主な要因は？

胃不全麻痺治療市場の成長は、糖尿病有病率の上昇、人口の高齢化、疾患に対する認識の高まりなど、いくつかの主要な要因によって牽引されています。胃不全麻痺は糖尿病、特に長期間コントロールされていない1型糖尿病や2型糖尿病と関連することが多く、胃の筋肉をコントロールする神経にダメージを与えます。世界の糖尿病の流行が増加するにつれ、胃不全麻痺の発生率も増加し、効果的な治療に対する需要が高まっています。さらに、糖尿病と胃不全麻痺の原因となる他の慢性疾患の有病率が高い高齢化も、市場成長を促進する重要な要因です。また、胃不全麻痺がQOLに大きな影響を与える衰弱性疾患であるという認識の高まりも、治療需要の拡大に寄与しています。医師やヘルスケアプロバイダーは、胃不全麻痺とその症状に対する認識を深めており、診断の向上と病態管理への注力の高まりにつながっています。このような認識の高まりと診断ツールの進歩が相まって、より多くの患者が治療を受けるようになっています。さらに、新しい薬理学的薬剤、低侵襲的治療、非侵襲的治療など、より効果的な治療法の開発は、胃不全麻痺管理におけるアンメットニーズへの対応に役立っています。さらに、胃不全麻痺に対する認識を高め、調査を促進することに焦点を当てた組織からのより多くの支援により、患者アドボカシーが活発化し、臨床試験やより良い治療法の研究への資金援助が増加しています。これらの要因が相まって、より効果的な管理戦略が利用できるようになり、この疾患に対する認識が広まるにつれて、胃不全麻痺治療市場の成長が促進されています。

胃不全麻痺治療市場成長の主な促進要因は？

胃不全麻痺治療市場の成長は、糖尿病罹患率の上昇、医学研究の進歩、革新的な治療オプションの増加に関連するいくつかの主要促進要因によって後押しされています。糖尿病患者数が世界的に増加し続ける中、胃不全麻痺は、特に長期にわたりコントロール不良の糖尿病患者において、より一般的になりつつあります。このため、症状を効果的に管理し、胃の運動性を改善する標的治療に対するニーズが高まっています。医学研究の進歩もまた、市場成長の推進に極めて重要な役割を果たしています。運動機能改善薬や制吐剤など、胃不全麻痺の背後にあるメカニズムを特異的に標的とする新しい薬剤製剤は、治療成績を向上させ、患者により良い症状コントロールを提供しています。難治例に対する胃電気刺激療法の開発も、従来の治療に反応しない患者のQOL向上に役立つ画期的なものです。さらに、個別化医療は胃不全麻痺の治療においてますます重要になってきており、個々の患者のニーズに基づいた、よりオーダーメイドの治療計画が必要となってきています。また、患者中心の医療が拡大し、栄養サポートや生活習慣への介入など、全体的な健康の改善に焦点が当てられていることも、市場拡大に寄与しています。さらに、ヘルスケアプロバイダーや患者による胃不全麻痺の認知度の向上、啓発活動や患者支援活動の活発化も、効果的な治療法に対する需要を促進しています。また、臨床試験や研究の利用可能性が拡大し、新たな治療法の発見や胃不全麻痺に対するより幅広い理解が進んでいることも、市場の追い風となっています。これらの促進要因が相まって、胃不全麻痺治療市場が継続的に成長し、患者の生活が向上し、治療の選択肢が拡大するための良好な環境が整いつつあります。

セグメント

薬剤クラス（運動促進薬クラス、制吐薬クラス、プロトンポンプ阻害薬クラス、その他薬剤クラス）、適応疾患（糖尿病性胃不全麻痺適応疾患、特発性胃不全麻痺適応疾患、術後胃不全麻痺適応疾患）、タイプ（一般用医薬品タイプ、処方薬タイプ）流通チャネル（病院薬局流通チャネル、小売薬局流通チャネル、オンライン薬局流通チャネル）、投与経路（経口投与経路、注射剤投与経路、経鼻投与経路）

調査対象企業の例（全34件）

• Abbott Laboratories
• AbbVie Inc.
• Alfa Wassermann S.p.A.
• AstraZeneca plc
• Bayer AG
• Boston Scientific Corp.
• Cardinal Health, Inc.
• Cipla Ltd.
• C.R. Bard, Inc.
• Enterra Medical, Inc.
• Evoke Pharma, Inc.
• Janssen Global Services
• Kimberly-Clark Corp.
• Medtronic plc
• Neurogastrx, Inc.
• Pfizer Inc.
• Rhythm Pharmaceuticals
• Salix Pharmaceuticals, Inc.
• Takeda Pharmaceutical Co.
• Teva Pharmaceutical Ind.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Gastroparesis Treatment Market to Reach US$7.7 Billion by 2030

The global market for Gastroparesis Treatment estimated at US$6.4 Billion in the year 2024, is expected to reach US$7.7 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Prokinetic Agents, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the Antiemetic Drugs segment is estimated at 2.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 6.3% CAGR

The Gastroparesis Treatment market in the U.S. is estimated at US$1.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 6.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Gastroparesis Treatment Market - Key Trends & Drivers Summarized

Why Is Gastroparesis Treatment Gaining Attention in the Gastroenterology Field?

Gastroparesis, a condition in which the stomach muscles are unable to move food through the digestive tract properly, is becoming an increasingly important focus in gastroenterology due to its growing prevalence and significant impact on patients' quality of life. This disorder, which often results from underlying conditions such as diabetes, can lead to symptoms like nausea, vomiting, bloating, early satiety, and severe abdominal discomfort. As the incidence of diabetes rises globally, the number of gastroparesis cases linked to diabetic neuropathy has also increased, making it a major concern in managing chronic conditions. The complexity of gastroparesis, with its multi-faceted causes and the variability of its symptoms, has made treatment a significant challenge. Patients often struggle with long-term management strategies, leading to high levels of frustration, reduced productivity, and an overall diminished quality of life. Additionally, gastroparesis frequently results in nutritional deficiencies and weight loss, making it not only a gastrointestinal issue but also a significant metabolic concern. Consequently, there is an increasing demand for more effective treatments, including drug therapies, dietary changes, and technological interventions, to better manage the condition. The growing awareness of gastroparesis and its association with other chronic diseases has led to greater research efforts and investment into finding solutions, with the aim of improving symptom control and patient outcomes.

How Are Advancements in Gastroparesis Treatments Improving Patient Care?

Advancements in the treatment of gastroparesis have greatly improved the ability to manage this challenging condition and enhance patient care. Traditionally, gastroparesis management has involved a combination of dietary modifications, prokinetic drugs, and symptomatic treatments aimed at alleviating nausea and vomiting. However, recent developments have expanded the range of treatment options and improved the effectiveness of symptom management. One of the key advancements has been the introduction of new prokinetic drugs that stimulate gastric motility. Drugs such as metoclopramide, which was historically the mainstay of treatment, are now being complemented by newer options, such as the dopamine antagonists and 5-HT4 agonists, that have fewer side effects and are better tolerated by patients. Additionally, gastric electrical stimulation (GES) has emerged as a promising treatment for patients with refractory gastroparesis who do not respond to conventional therapies. This technique involves implanting a device that delivers electrical pulses to the stomach muscles, improving motility and alleviating symptoms like nausea and vomiting. Another breakthrough in treatment has been the use of intravenous therapies such as antiemetics and fluids to manage dehydration and nutritional deficiencies that are common in patients with severe gastroparesis. Furthermore, dietary management has also advanced with specialized nutritional interventions, including the use of liquid meal replacements and enteral feeding when necessary, ensuring that patients maintain adequate nutrition while managing the condition. These advancements, combined with improved diagnostic techniques such as gastric emptying scintigraphy, which helps in assessing the severity of the condition, are enabling more personalized and effective treatment plans for individuals suffering from gastroparesis.

What Are the Key Factors Driving the Growth of the Gastroparesis Treatment Market?

The growth of the gastroparesis treatment market is driven by several key factors, including the rising prevalence of diabetes, an aging population, and increasing awareness of the condition. Gastroparesis is often associated with diabetes, particularly long-term uncontrolled type 1 and type 2 diabetes, which leads to damage to the nerves that control stomach muscles. As the global diabetes epidemic continues to rise, so does the incidence of gastroparesis, creating a growing demand for effective treatments. Additionally, the aging population, with its higher prevalence of both diabetes and other chronic conditions that contribute to gastroparesis, is another key factor driving market growth. The increasing recognition of gastroparesis as a debilitating condition that significantly impacts quality of life has also contributed to the growing demand for treatments. Physicians and healthcare providers are becoming more aware of gastroparesis and its symptoms, leading to better diagnosis and an increased focus on managing the condition. This increased recognition, coupled with advances in diagnostic tools, is encouraging more patients to seek treatment. Furthermore, the development of more effective treatment options, including newer pharmacological agents, minimally invasive procedures, and non-invasive therapies, has helped address the unmet needs in gastroparesis management. Additionally, increased patient advocacy, with more support from organizations focused on raising awareness of gastroparesis and promoting research, has led to greater funding for clinical trials and research into better treatment options. Together, these factors are driving growth in the gastroparesis treatment market as more effective management strategies become available and awareness of the condition spreads.

What Are the Primary Drivers Behind the Growth of the Gastroparesis Treatment Market?

The growth of the gastroparesis treatment market is fueled by several key drivers related to the rising incidence of the condition, advancements in medical research, and the increased availability of innovative treatment options. As the number of individuals with diabetes continues to grow globally, gastroparesis is becoming more common, particularly in patients with long-standing, poorly controlled diabetes. This is creating a growing need for targeted treatments that can effectively manage the symptoms and improve gastric motility. Advances in medical research have also played a pivotal role in driving market growth. New drug formulations that specifically target the mechanisms behind gastroparesis, such as motility agents and antiemetics, are improving treatment outcomes and offering patients better symptom control. The development of gastric electrical stimulation therapy for refractory cases is another breakthrough that is helping to improve quality of life for patients who do not respond to conventional treatments. Furthermore, personalized medicine is becoming increasingly important in the treatment of gastroparesis, with more tailored treatment plans based on individual patient needs. The growth of patient-centered care and the focus on improving overall well-being, including nutritional support and lifestyle interventions, is also contributing to the expanding market. Additionally, the increasing recognition of gastroparesis by healthcare providers and patients, coupled with greater awareness efforts and patient advocacy, is driving demand for effective therapies. The market is also benefiting from the expanding availability of clinical trials and research, leading to the discovery of new treatments and a broader understanding of the condition. Together, these drivers are creating a favorable environment for the continued growth of the gastroparesis treatment market, improving the lives of patients and expanding therapeutic options.

SCOPE OF STUDY:

The report analyzes the Gastroparesis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class, Other Drug Classes); Disease Indication (Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication, Post-surgical Gastroparesis Disease Indication); Type (Over-the-Counter Drugs Type, Prescription Drugs Type)Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel); Administration Route (Oral Administration Route, Injectables Administration Route, Nasal Administration Route)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Abbott Laboratories
• AbbVie Inc.
• Alfa Wassermann S.p.A.
• AstraZeneca plc
• Bayer AG
• Boston Scientific Corp.
• Cardinal Health, Inc.
• Cipla Ltd.
• C.R. Bard, Inc.
• Enterra Medical, Inc.
• Evoke Pharma, Inc.
• Janssen Global Services
• Kimberly-Clark Corp.
• Medtronic plc
• Neurogastrx, Inc.
• Pfizer Inc.
• Rhythm Pharmaceuticals
• Salix Pharmaceuticals, Inc.
• Takeda Pharmaceutical Co.
• Teva Pharmaceutical Ind.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Gastroparesis Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Gastroparesis and Other Digestive Disorders Drives Demand for Effective Treatments
  • Here's the Story: How Advancements in Pharmacological Therapies Are Expanding Treatment Options for Gastroparesis
  • Growing Focus on Personalized Medicine in Gastroenterology Strengthens the Business Case for Tailored Gastroparesis Treatments
  • Increasing Awareness and Diagnosis of Gastroparesis Accelerates Adoption of Medical Interventions
  • Technological Innovations in Gastric Stimulation and Neurostimulation Devices Expand Treatment Horizons for Gastroparesis
  • Rising Prevalence of Diabetes and Neurological Disorders Contributes to the Growing Market for Gastroparesis Solutions
  • Here's How Advances in Nutritional Management and Dietary Therapies Are Enhancing Gastroparesis Treatment Protocols
  • Surge in Demand for Non-Invasive and Minimally Invasive Treatment Options Increases Interest in New Therapeutics
  • Growing Market for Combination Therapies and Multi-Modal Approaches Drives Development of More Effective Gastroparesis Drugs
  • Rising Demand for Wearable Devices for Monitoring Gastroparesis Symptoms Enhances Patient Quality of Life
  • Rising Popularity of Home Care Solutions and Support for Chronic Conditions Drives Market Expansion
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Gastroparesis Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Gastroparesis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Gastroparesis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Gastroparesis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Prokinetic Agents Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Prokinetic Agents Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Prokinetic Agents Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Antiemetic Drugs Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Antiemetic Drugs Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Antiemetic Drugs Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Proton Pump Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Proton Pump Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Proton Pump Inhibitors Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Oral Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Injectables Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Injectables Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Injectables Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Nasal Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Nasal Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Nasal Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Diabetes Gastroparesis Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Diabetes Gastroparesis Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Diabetes Gastroparesis Disease Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Idiopathic Gastroparesis Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Idiopathic Gastroparesis Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Idiopathic Gastroparesis Disease Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Post-surgical Gastroparesis Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Post-surgical Gastroparesis Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Post-surgical Gastroparesis Disease Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Over-the-Counter Drugs Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Over-the-Counter Drugs Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Over-the-Counter Drugs Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Prescription Drugs Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Prescription Drugs Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Prescription Drugs Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• JAPAN
  • Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• CHINA
  • Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 77: China Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• EUROPE
  • Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Gastroparesis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Gastroparesis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Gastroparesis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• FRANCE
  • Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 104: France Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: France 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• GERMANY
  • Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Germany 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Germany 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Italy 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Italy 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Italy 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Italy 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 140: UK Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: UK Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: UK 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 143: UK Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: UK 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: UK 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: UK 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 152: Spain Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Spain Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Spain 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Spain 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Spain 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Spain 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 164: Russia Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Russia Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Russia 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Russia 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Russia 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Russia 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Europe Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Europe 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Gastroparesis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 189: Asia-Pacific Historic Review for Gastroparesis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Asia-Pacific 15-Year Perspective for Gastroparesis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 203: Australia Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Australia Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Australia 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Australia 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Australia 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Australia 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• INDIA
  • Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 215: India Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: India Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: India 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 218: India Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: India 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: India 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: India 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 227: South Korea Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: South Korea Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: South Korea 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: South Korea 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: South Korea 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: South Korea 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Asia-Pacific Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 251: Latin America Recent Past, Current & Future Analysis for Gastroparesis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 252: Latin America Historic Review for Gastroparesis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Latin America 15-Year Perspective for Gastroparesis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Latin America 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 266: Argentina Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Argentina Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Argentina 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Argentina 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Argentina 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Argentina 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 278: Brazil Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Brazil Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Brazil 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Brazil 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Brazil 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Brazil 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 290: Mexico Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Mexico Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Mexico 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Mexico 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Mexico 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Mexico 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Latin America Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Latin America 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 314: Middle East Recent Past, Current & Future Analysis for Gastroparesis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 315: Middle East Historic Review for Gastroparesis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Middle East 15-Year Perspective for Gastroparesis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Middle East 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 329: Iran Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Iran Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Iran 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Iran 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Iran 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Iran 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 341: Israel Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Israel Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Israel 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Israel 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Israel 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Israel 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Saudi Arabia Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Saudi Arabia 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 365: UAE Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: UAE Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: UAE 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: UAE 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: UAE 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: UAE 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Rest of Middle East Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Rest of Middle East 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030
• AFRICA
  • Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 389: Africa Recent Past, Current & Future Analysis for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Africa Historic Review for Gastroparesis Treatment by Drug Class - Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Africa 15-Year Perspective for Gastroparesis Treatment by Drug Class - Percentage Breakdown of Value Sales for Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Gastroparesis Treatment by Administration Route - Oral Administration Route, Injectables Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Africa 15-Year Perspective for Gastroparesis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Nasal Administration Route for the Years 2015, 2025 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Gastroparesis Treatment by Disease Indication - Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Africa 15-Year Perspective for Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication and Post-surgical Gastroparesis Disease Indication for the Years 2015, 2025 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Gastroparesis Treatment by Type - Over-the-Counter Drugs Type and Prescription Drugs Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Africa 15-Year Perspective for Gastroparesis Treatment by Type - Percentage Breakdown of Value Sales for Over-the-Counter Drugs Type and Prescription Drugs Type for the Years 2015, 2025 & 2030

IV. COMPETITION